ARDM Awaits Data In Q4, FDA Clears TCMD Device, Newfound Interest For GLMD, GALT

Aradigm Corp.'s (ARDM) two phase III studies of its investigational drug Pulmaquin in patients with non-cystic fibrosis bronchiectasis are proceeding as planned. The top-line data from the two trials are expected to be available in the fourth quarter of this year.

from RTT - Biotech http://ift.tt/2dffY9U
via IFTTT